PI3Kδinhibitors as immunomodulatory agents for the treatment of lymphoma patients
Additional information
Authors
Tarantelli C.,
Argnani L.,
Zinzani P. L.,
Bertoni F.
Type
Journal Article
Year
2021
Language
English
Abstract
The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδinhibitors exert on the immune system with a particular focus on the T-cell compartment.
Keywords
Lymphoma, PI3K inhibitors, T-cells, B-cells, Macrophages, Chemokine, Cancer, Tumor, Immune checkpoint inhibitors
Journal
Cancers
Volume
13
Pages (or article number)
5535.
Diffusion
License
CC BY
Visibility
Public
Status open access
Gold
